Developer docs
API playgroundTry for free, no card

Search company profiles

SetPoint Medical

Full company profile

uuid00002w8

Namestring
SetPoint Medical
Legal namestring
SetPoint Medical Corporation
Company typeenum
Private
Founded yearint
2007
Descriptiontext

SetPoint Medical is a Valencia, California-based medical device company founded in 2007 that has developed the SetPoint System, the first and only FDA-approved neuroimmune modulation device for the treatment of rheumatoid arthritis. The company was founded on Dr. Kevin Tracey's pioneering research demonstrating that vagus nerve stimulation activates the cholinergic anti-inflammatory pathway, and over nearly two decades translated that science into a miniaturized, leadless, rechargeable implantable neurostimulator placed directly on the left vagus nerve. The device automatically delivers one minute of therapy daily for up to 10 years, reducing proinflammatory cytokines (TNF, IL-6, IL-1β) by 30-70% through activation of innate anti-inflammatory pathways without suppressing the immune system. The pivotal RESET-RA trial enrolled 242 patients and demonstrated 98% therapy persistence at 12 months, 49.3% achieving DAS28-CRP low disease activity or remission, and a 50% relative reduction in joint erosion progression.

SetPoint Medical generates revenue through one-time hardware sales of the SetPoint System implant plus the surgical procedure, with reimbursement supported by a dedicated HCPCS code C1607 and CMS Transitional Pass-Through payment status effective January 2026. The company employs a direct field sales model using Territory Managers who build referral pathways between prescribing rheumatologists and implanting functional neurosurgeons, supplemented by SetPoint Activators who support patients through prior authorization and onboarding. Commercial launch in the U.S. is targeting biologic-experienced RA patients as the primary indication, with named early-adopter centers including Northwell Health, Rush University Medical Center, Ascension Dell Seton Medical Center, and St. John's Regional Medical Center. The company has also initiated a pilot study in relapsing-remitting multiple sclerosis supported by FDA Breakthrough Device Designation, representing a platform expansion into additional autoimmune indications.

The company has raised approximately $140M in its most recent 2025 financing (including $25M Series C and $115M Series D) co-led by Elevage Medical Technologies and Ally Bridge Group, with strategic participation from Abbott, Boston Scientific, Northwell Health, and a syndicate of venture investors. Total capital raised across all funding rounds exceeds $400M including debt. The leadership team combines commercial experience from prior medtech IPOs (Evolus, Intersect ENT, Cutera) with deep neuromodulation expertise (Abbott, Medtronic, Inspire Medical, MicroTransponder), positioning the company for commercial execution following its July 2025 FDA approval.

Short descriptiontext

SetPoint Medical is a Valencia, California-based medical device company that developed the first FDA-approved vagus nerve stimulation device for rheumatoid arthritis. It sells the SetPoint System, a miniaturized implantable neurostimulator that activates innate anti-inflammatory pathways to treat biologic-experienced RA patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersValencia, United States
HQ citystring
Valencia
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
implantable neurostimulator devices, vagal nerve stimulation therapy, neuroimmune modulation platform, bioelectronic medicine devices, rheumatoid arthritis treatment
Industry3 codes
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAA
General Neurology
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
NAICS code1 code
  • Scientific Research and Development Services5417
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Implantable Bioelectronic Neurostimulators
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1SetPoint System Implant Device Sales
TypeHardware Sales
Description

The SetPoint System is sold as an implantable medical device. The one-time procedure includes device placement with upfront costs for the implant and surgical procedure. The device is designed to provide therapy for up to 10 years, representing a long-term treatment relationship with patients. Revenue is generated from device sales to healthcare facilities and providers.

setpointmedical.com
2Healthcare Procedure Reimbursement
TypeTransaction Fee
Description

SetPoint Medical generates revenue through healthcare procedure reimbursement. CMS granted Transitional Pass-Through (TPT) payment status effective January 1, 2026, creating new HCPCS device category C1607. Commercial insurance, Medicare, and Medicaid may cover SetPoint System on a case-by-case basis with prior authorization.

setpointmedical.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations
Pricing details2 tiers
1SetPoint System - Implant and Procedure
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

One-time implant procedure cost that includes the device and surgical placement. Costs vary by surgical facility, insurance coverage, deductibles, copays, and coinsurance. Once implanted, there are no additional costs to continue using the SetPoint System for up to 10 years of therapy.

setpointmedical.com
2External Components (Charger, Docking Station)
ModelUnit PricingBilling cadenceMulti-year contract
Notes

External components including Charger and Docking Station have a 5-year service life and can be replaced by rheumatologist as needed. These are included with the initial system.

setpointmedical.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1SetPoint System
Description

FDA-approved neuroimmune modulation device for treating rheumatoid arthritis through vagus nerve stimulation

setpointmedical.com
+2 more records
Core offering1 text field

SetPoint Medical develops, manufactures, and commercializes the SetPoint System, an FDA-approved implantable neurostimulator placed on the left vagus nerve that automatically delivers one minute of daily therapy for up to 10 years to treat moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to biologics or JAK inhibitors. The company also advances investigational neuroimmune modulation applications for multiple sclerosis and Crohn's disease.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 98% of patients remained on SetPoint Therapy through 12 months in RESET-RA study
+5 more records
Product overview1 text field

SetPoint Medical offers the SetPoint System, an FDA-approved neuroimmune modulation therapy platform for rheumatoid arthritis. The core product consists of the SetPoint System - a miniaturized implantable neurostimulator placed on the vagus nerve that delivers one-minute daily electrical stimulation to activate innate anti-inflammatory pathways. The system includes the implantable device, wireless charger, docking station, and supporting components. The company is also advancing pipeline applications for multiple sclerosis and Crohn's disease.

Product and service4 records
1SetPoint System
CategoryImplantable neurostimulator for rheumatoid arthritis
Description

FDA-approved neuroimmune modulation device consisting of a small, wireless, rechargeable, integrated neurostimulator enclosed in a ceramic and titanium case that is placed directly on the left vagus nerve to deliver precise electrical pulses for treatment of rheumatoid arthritis. The system includes the implantable device, wireless charger, docking station, and therapy management cards, and is indicated for adults with moderately to severely active RA who have had inadequate response or intolerance to biologics or JAK inhibitors.

2SetPoint Implant
CategoryImplantable neurostimulator component
Description

The implantable component of the SetPoint System - a small, leadless, integrated neurostimulator placed on the left vagus nerve within a flexible silicone Pod that automatically delivers therapy for one minute each day for up to 10 years. Features a rechargeable battery and integrated telemetry.

3SetPoint Charger
CategoryExternal accessory for implantable neurostimulator
Description

Wireless neck-worn charger used to recharge the SetPoint Implant for a few minutes each week. Includes docking station for storage and carrying case for travel. Designed to last up to 5 years and replaceable by the rheumatologist as needed.

4SetPoint Docking Station
CategoryExternal accessory for implantable neurostimulator
Description

Charging station for the SetPoint Charger, designed to keep the charger fully charged when not in use. Part of the external component system for the SetPoint Implant.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis. Dr. Jacqueline Rosenthal serves as principal investigator. First patients enrolled in April 2026.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

3Minnesota Center for Multiple Sclerosis
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis. Part of multicenter randomized sham-controlled double-blind study enrolling up to 60 patients.

setpointmedical.com
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2026-04-30
Description

Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1MicroTransponder
TypeDirect peer
Description

MicroTransponder is a closely comparable privately-held neurostimulation company developing implantable vagus nerve stimulation therapy, most notably for post-stroke recovery and other chronic conditions. Like SetPoint, it is pursuing FDA-approved VNS-based therapeutics for chronic diseases, operates at similar scale, and shares the SetPoint VP of Market Access (Spencer Bailey came from MicroTransponder). Direct overlap in implantable VNS mechanism and indication-expansion strategy.

TypeDirect peer
Description

electroCore develops non-invasive vagus nerve stimulation (nVNS) therapy, including FDA-cleared gammaCore for migraine and cluster headache. It is the most direct VNS-mechanism competitor to SetPoint, pursuing vagus nerve stimulation as a platform across multiple indications, though its non-invasive delivery differs from SetPoint's implantable approach.

TypeBroad incumbent
Description

LivaNova (formerly Cyberonics) is the established market leader in implantable vagus nerve stimulation, with its VNS Therapy system FDA-approved for drug-resistant epilepsy and treatment-resistant depression. It pioneered the implantable VNS category SetPoint operates in and represents the most relevant scaled implantable-VNS comparable, though its indications are neurology rather than autoimmune.

TypeDirect peer
Description

Inspire Medical Systems is a commercial-stage implantable neurostimulation company (hypoglossal nerve stimulation for obstructive sleep apnea) with a similar profile to SetPoint: FDA-approved Class III implantable device, US-focused direct-to-physician sales model, and successful execution from startup to commercial scale and IPO. Closely analogous business model and go-to-market motion.

TypeDirect peer
Description

CVRx is a commercial-stage company developing Barostim, an implantable neuromodulation device for heart failure and resistant hypertension. Comparable to SetPoint in being a venture-backed, FDA-approved implantable neuromodulation company pursuing chronic disease indications with similar regulatory and commercialization pathways.

TypeDirect peer
Description

Axonics develops and commercializes implantable sacral neuromodulation systems for incontinence and overactive bladder. It shares SetPoint's profile as a venture-backed, FDA-approved implantable neuromodulation company with miniaturized rechargeable technology, a similar commercial launch trajectory, and overlap in venture investors (e.g., some of the same healthcare-focused funds).

TypeEmerging player
Description

Galvani Bioelectronics is a joint venture between GlaxoSmithKline and Verily (Alphabet) developing bioelectronic medicines that use implantable devices to modulate neural signals for chronic diseases, including autoimmune indications. Conceptually the closest large-scale strategic peer to SetPoint's neuroimmune modulation thesis, with substantially greater resources but earlier-stage clinical pipeline.

TypeBroad incumbent
Description

Nevro is a commercial-stage neuromodulation company with its Senza spinal cord stimulation system for chronic pain, a publicly-traded scaled neuromodulation player. Relevant as a comparable implantable neurostim business model, though its indication (chronic pain) and mechanism (spinal cord stimulation) differ from SetPoint's vagus nerve approach.

TypeBroad incumbent
Description

Medtronic is a global medical device leader with a broad neuromodulation portfolio including VNS, spinal cord stimulation, and deep brain stimulation, and is a historical SetPoint investor. Represents the large incumbent competitive and potential strategic-acquirer reference point for implantable neurostimulation markets.

TypeBroad incumbent
Description

Abbott operates a major neuromodulation franchise (Proclaim DRG, Proclaim Infinity, Infinity OCTRODE) and is a SetPoint investor. Comparable as a broad incumbent neuromodulation platform with the strategic optionality to acquire SetPoint's neuroimmune platform as an adjacency to its existing pain and movement disorder franchises.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds15 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors33 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SetPoint Medical

Implantable Bioelectronic Neurostimulatorssetpointmedical.com

SetPoint Medical is a Valencia, California-based medical device company that developed the first FDA-approved vagus nerve stimulation device for rheumatoid arthritis. It sells the SetPoint System, a miniaturized implantable neurostimulator that activates innate anti-inflammatory pathways to treat biologic-experienced RA patients.

What SetPoint Medical does

SetPoint Medical is a Valencia, California-based medical device company founded in 2007 that has developed the SetPoint System, the first and only FDA-approved neuroimmune modulation device for the treatment of rheumatoid arthritis. The company was founded on Dr. Kevin Tracey's pioneering research demonstrating that vagus nerve stimulation activates the cholinergic anti-inflammatory pathway, and over nearly two decades translated that science into a miniaturized, leadless, rechargeable implantable neurostimulator placed directly on the left vagus nerve. The device automatically delivers one minute of therapy daily for up to 10 years, reducing proinflammatory cytokines (TNF, IL-6, IL-1β) by 30-70% through activation of innate anti-inflammatory pathways without suppressing the immune system. The pivotal RESET-RA trial enrolled 242 patients and demonstrated 98% therapy persistence at 12 months, 49.3% achieving DAS28-CRP low disease activity or remission, and a 50% relative reduction in joint erosion progression.

SetPoint Medical generates revenue through one-time hardware sales of the SetPoint System implant plus the surgical procedure, with reimbursement supported by a dedicated HCPCS code C1607 and CMS Transitional Pass-Through payment status effective January 2026. The company employs a direct field sales model using Territory Managers who build referral pathways between prescribing rheumatologists and implanting functional neurosurgeons, supplemented by SetPoint Activators who support patients through prior authorization and onboarding. Commercial launch in the U.S. is targeting biologic-experienced RA patients as the primary indication, with named early-adopter centers including Northwell Health, Rush University Medical Center, Ascension Dell Seton Medical Center, and St. John's Regional Medical Center. The company has also initiated a pilot study in relapsing-remitting multiple sclerosis supported by FDA Breakthrough Device Designation, representing a platform expansion into additional autoimmune indications.

The company has raised approximately $140M in its most recent 2025 financing (including $25M Series C and $115M Series D) co-led by Elevage Medical Technologies and Ally Bridge Group, with strategic participation from Abbott, Boston Scientific, Northwell Health, and a syndicate of venture investors. Total capital raised across all funding rounds exceeds $400M including debt. The leadership team combines commercial experience from prior medtech IPOs (Evolus, Intersect ENT, Cutera) with deep neuromodulation expertise (Abbott, Medtronic, Inspire Medical, MicroTransponder), positioning the company for commercial execution following its July 2025 FDA approval.

SetPoint Medical firmographics

Firmographics
Name
SetPoint Medical
Legal name
SetPoint Medical Corporation
Website
https://setpointmedical.com
Company type
Private
Founded year
2007
Operating status
Operating
Headcount range
101–250 employees
Short description
SetPoint Medical is a Valencia, California-based medical device company that developed the first FDA-approved vagus nerve stimulation device for rheumatoid arthritis. It sells the SetPoint System, a miniaturized implantable neurostimulator that activates innate anti-inflammatory pathways to treat biologic-experienced RA patients.
Ownership category
akta.pro rank

SetPoint Medical industry classification

Industry
Product category
Implantable Bioelectronic Neurostimulators
NAICS
Scientific Research and Development Services (5417)
SIC
Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro industry
PRIMARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
SECONDARYHLAKAIAA
General Neurology
SECONDARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology

Keywords

  • Implantable neurostimulator devices
  • Vagal nerve stimulation therapy
  • Neuroimmune modulation platform
  • Bioelectronic medicine devices
  • Rheumatoid arthritis treatment

Where SetPoint Medical is headquartered

Location

Headquarters

HQ city
Valencia
HQ country
United States
HQ region
North America

Offices1 record

Markets served

SetPoint Medical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations

Revenue model

  1. SetPoint System Implant Device Sales: The SetPoint System is sold as an implantable medical device. The one-time procedure includes device placement with upfront costs for the implant and surgical procedure. The device is designed to provide therapy for up to 10 years, representing a long-term treatment relationship with patients. Revenue is generated from device sales to healthcare facilities and providers.
  2. Healthcare Procedure Reimbursement: SetPoint Medical generates revenue through healthcare procedure reimbursement. CMS granted Transitional Pass-Through (TPT) payment status effective January 1, 2026, creating new HCPCS device category C1607. Commercial insurance, Medicare, and Medicaid may cover SetPoint System on a case-by-case basis with prior authorization.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractSetPoint System - Implant and Procedure
Unit PricingMulti-year contractExternal Components (Charger, Docking Station)

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

SetPoint Medical product offering

Product offering

Core offering

SetPoint Medical develops, manufactures, and commercializes the SetPoint System, an FDA-approved implantable neurostimulator placed on the left vagus nerve that automatically delivers one minute of daily therapy for up to 10 years to treat moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to biologics or JAK inhibitors. The company also advances investigational neuroimmune modulation applications for multiple sclerosis and Crohn's disease.

Product overview

SetPoint Medical offers the SetPoint System, an FDA-approved neuroimmune modulation therapy platform for rheumatoid arthritis. The core product consists of the SetPoint System - a miniaturized implantable neurostimulator placed on the vagus nerve that delivers one-minute daily electrical stimulation to activate innate anti-inflammatory pathways. The system includes the implantable device, wireless charger, docking station, and supporting components. The company is also advancing pipeline applications for multiple sclerosis and Crohn's disease.

Differentiator

Problem solved

Functional benefit

Brands

  • SetPoint System: FDA-approved neuroimmune modulation device for treating rheumatoid arthritis through vagus nerve stimulation
  • SetPoint Therapy
  • RESET-RA

Products and services

  • SetPoint System FDA-approved neuroimmune modulation device consisting of a small, wireless, rechargeable, integrated neurostimulator enclosed in a ceramic and titanium case that is placed directly on the left vagus nerve to deliver precise electrical pulses for treatment of rheumatoid arthritis. The system includes the implantable device, wireless charger, docking station, and therapy management cards, and is indicated for adults with moderately to severely active RA who have had inadequate response or intolerance to biologics or JAK inhibitors.
  • SetPoint Implant The implantable component of the SetPoint System - a small, leadless, integrated neurostimulator placed on the left vagus nerve within a flexible silicone Pod that automatically delivers therapy for one minute each day for up to 10 years. Features a rechargeable battery and integrated telemetry.
  • SetPoint Charger Wireless neck-worn charger used to recharge the SetPoint Implant for a few minutes each week. Includes docking station for storage and carrying case for travel. Designed to last up to 5 years and replaceable by the rheumatologist as needed.
  • SetPoint Docking Station Charging station for the SetPoint Charger, designed to keep the charger fully charged when not in use. Part of the external component system for the SetPoint Implant.

Quantifiable outcome

  • 98% of patients remained on SetPoint Therapy through 12 months in RESET-RA study
  • +5 more outcomes

Companies that use SetPoint Medical

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles2 records

SetPoint Medical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

SetPoint Medical partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered major.

  • Shepherd Center's Andrew C. Carlos MS InstitutemajorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis. Dr. Jacqueline Rosenthal serves as principal investigator. First patients enrolled in April 2026.
  • UW Medicine Multiple Sclerosis Center (Seattle)majorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.
  • Minnesota Center for Multiple SclerosismajorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis. Part of multicenter randomized sham-controlled double-blind study enrolling up to 60 patients.
  • Johns Hopkins UniversitymajorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.
  • West Virginia UniversitymajorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.
  • UT Medicine Multiple Sclerosis and Neuroimmunology Center (Austin)majorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.
  • University of Texas Health Science Center (Houston)majorStrategic or Co-development Partner · 30 April 2026Clinical study site for pilot clinical study evaluating SetPoint System for relapsing-remitting multiple sclerosis.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

SetPoint Medical competitors and assessment

Company assessment

Direct peers

  • MicroTransponder: MicroTransponder is a closely comparable privately-held neurostimulation company developing implantable vagus nerve stimulation therapy, most notably for post-stroke recovery and other chronic conditions. Like SetPoint, it is pursuing FDA-approved VNS-based therapeutics for chronic diseases, operates at similar scale, and shares the SetPoint VP of Market Access (Spencer Bailey came from MicroTransponder). Direct overlap in implantable VNS mechanism and indication-expansion strategy.
  • electroCore: electroCore develops non-invasive vagus nerve stimulation (nVNS) therapy, including FDA-cleared gammaCore for migraine and cluster headache. It is the most direct VNS-mechanism competitor to SetPoint, pursuing vagus nerve stimulation as a platform across multiple indications, though its non-invasive delivery differs from SetPoint's implantable approach.
  • Inspire Medical Systems: Inspire Medical Systems is a commercial-stage implantable neurostimulation company (hypoglossal nerve stimulation for obstructive sleep apnea) with a similar profile to SetPoint: FDA-approved Class III implantable device, US-focused direct-to-physician sales model, and successful execution from startup to commercial scale and IPO. Closely analogous business model and go-to-market motion.
  • CVRx: CVRx is a commercial-stage company developing Barostim, an implantable neuromodulation device for heart failure and resistant hypertension. Comparable to SetPoint in being a venture-backed, FDA-approved implantable neuromodulation company pursuing chronic disease indications with similar regulatory and commercialization pathways.
  • Axonics Modulation Technologies: Axonics develops and commercializes implantable sacral neuromodulation systems for incontinence and overactive bladder. It shares SetPoint's profile as a venture-backed, FDA-approved implantable neuromodulation company with miniaturized rechargeable technology, a similar commercial launch trajectory, and overlap in venture investors (e.g., some of the same healthcare-focused funds).

Broad incumbents

  • LivaNova: LivaNova (formerly Cyberonics) is the established market leader in implantable vagus nerve stimulation, with its VNS Therapy system FDA-approved for drug-resistant epilepsy and treatment-resistant depression. It pioneered the implantable VNS category SetPoint operates in and represents the most relevant scaled implantable-VNS comparable, though its indications are neurology rather than autoimmune.
  • Nevro Corp: Nevro is a commercial-stage neuromodulation company with its Senza spinal cord stimulation system for chronic pain, a publicly-traded scaled neuromodulation player. Relevant as a comparable implantable neurostim business model, though its indication (chronic pain) and mechanism (spinal cord stimulation) differ from SetPoint's vagus nerve approach.
  • Medtronic: Medtronic is a global medical device leader with a broad neuromodulation portfolio including VNS, spinal cord stimulation, and deep brain stimulation, and is a historical SetPoint investor. Represents the large incumbent competitive and potential strategic-acquirer reference point for implantable neurostimulation markets.
  • Abbott: Abbott operates a major neuromodulation franchise (Proclaim DRG, Proclaim Infinity, Infinity OCTRODE) and is a SetPoint investor. Comparable as a broad incumbent neuromodulation platform with the strategic optionality to acquire SetPoint's neuroimmune platform as an adjacency to its existing pain and movement disorder franchises.

Emerging players

  • Galvani Bioelectronics: Galvani Bioelectronics is a joint venture between GlaxoSmithKline and Verily (Alphabet) developing bioelectronic medicines that use implantable devices to modulate neural signals for chronic diseases, including autoimmune indications. Conceptually the closest large-scale strategic peer to SetPoint's neuroimmune modulation thesis, with substantially greater resources but earlier-stage clinical pipeline.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

SetPoint Medical social profiles

Digital presence

SetPoint Medical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SetPoint Medical leadership team

Management profile

Number of profiles

Profiles19 records

SetPoint Medical funding detail

Funding detail

Funding overview

Funding rounds15 records

Investors33 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SetPoint Medical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SetPoint Medical

What does SetPoint Medical do?

SetPoint Medical develops, manufactures, and commercializes the SetPoint System, an FDA-approved implantable neurostimulator placed on the left vagus nerve that automatically delivers one minute of daily therapy for up to 10 years to treat moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to biologics or JAK inhibitors. The company also advances investigational neuroimmune modulation applications for multiple sclerosis and Crohn's disease.

Is SetPoint Medical a public or private company?

SetPoint Medical is a private company. It is classified as venture growth investor backed and is currently operating.

When was SetPoint Medical founded?

SetPoint Medical was founded in 2007. It employs 101 to 250 people.

Where is SetPoint Medical based?

SetPoint Medical is headquartered in Valencia, United States, in the North America region.

How does SetPoint Medical make money?

Two revenue lines are on record. SetPoint System Implant Device Sales are the primary driver. The others are healthcare Procedure Reimbursement.

Who are SetPoint Medical's main competitors?

Direct peers on record are MicroTransponder, electroCore, Inspire Medical Systems, CVRx and Axonics Modulation Technologies. Broad incumbents are LivaNova, Nevro Corp, Medtronic and Abbott. Galvani Bioelectronics is listed as an emerging player.

Does SetPoint Medical have an API?

No public API is recorded for SetPoint Medical.

What industry is SetPoint Medical in?

SetPoint Medical's product category is Implantable Bioelectronic Neurostimulators. Its primary akta.pro industry code is HLAHAEAK, Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS), with a secondary code of HLAKAIAA, General Neurology. Its NAICS code is 5417 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSetPoint Medical Presents 24-Month Data Demonstrating Sustained Clinical Benefit and Favorable Long-Term Safety of the SetPoint® System for Rheumatoid ArthritisSetPoint Medical presented 24-month data from its RESET-RA trial at ACR Convergence 2026, showing sustained clinical responses with the SetPoint System for rheumatoid arthritis. Among 242 participants, 71% reached 24-month follow-up without adding biologic or targeted synthetic drugs, and 62.7% achieved ACR20 response. The company plans to expand patient access in 2027.PR NewswireSetPoint Medical Announces First SetPoint® System Procedures in New Mexico, Performed at University of New Mexico HospitalSetPoint Medical announced the first SetPoint System procedures in New Mexico, performed at University of New Mexico Hospital by neurosurgeon James Botros. The FDA-approved neuroimmune modulation therapy targets rheumatoid arthritis patients who failed biologic or targeted synthetic DMARDs. The company plans to evaluate its platform for multiple sclerosis and Crohn's disease.TrendHunter.comImplantable Arthritis Treatment DevicesSetPoint Medical used its FDA-approved SetPoint System at Beth Israel Deaconess Medical Center in Boston for the first time, offering an implantable vagus nerve stimulation therapy for adults with difficult-to-manage rheumatoid arthritis. The outpatient procedure provides an alternative to additional medication for patients with limited treatment success. The company is exploring potential applications for multiple sclerosis and Crohn's disease.YahooSetPoint treats first patient with neuroimmune modulation systemSetPoint Medical treated its first patient with its neuroimmune modulation system at Boston's BIDMC, where Dr. Joshua Aronson performed the procedure. The FDA-approved device stimulates the left vagus nerve to trigger anti-inflammatory processes for rheumatoid arthritis. SetPoint plans to investigate the platform for Crohn's disease and multiple sclerosis.Medical Device NetworkSetPoint treats first patient with neuroimmune modulation systemSetPoint Medical treated its first patient with the SetPoint neuroimmune modulation system at BIDMC, where Dr Joshua Aronson performed the surgery. The FDA-approved device delivers electrical pulses to the left vagus nerve to regulate immune activity in rheumatoid arthritis. The company plans to explore the platform for Crohn's disease and multiple sclerosis.PR NewswireSetPoint Medical Announces First SetPoint® System Procedure in Boston at Beth Israel Deaconess Medical CenterSetPoint Medical announced the first patient treated with its SetPoint System at Beth Israel Deaconess Medical Center in Boston. The FDA-approved neuroimmune modulation therapy targets the vagus nerve for rheumatoid arthritis, with over 1.5 million Americans affected. The company plans to evaluate the platform for multiple sclerosis and Crohn's disease.Medical BuyerSetPoint Medical appoints Dan Dearen to boardSetPoint Medical appointed Dan Dearen to its Board of Directors. Dearen brings nearly 40 years of executive experience, including leading Axonics, which Boston Scientific acquired for $3.7 billion in 2024. He will help scale SetPoint's commercial operations and advance its pipeline.PR NewswireSetPoint Medical Appoints Dan Dearen to Its Board of DirectorsSetPoint Medical appointed Dan Dearen to its board of directors, bringing nearly 40 years of medical device and life sciences leadership. Dearen previously led Axonics, which Boston Scientific acquired for $3.7 billion in 2024. He will help scale SetPoint's commercial operations and advance its pipeline.PR NewswireSetPoint® System Used for First Time in Pacific Northwest to Treat Patients with Rheumatoid Arthritis in Clinical PracticeOregon Health & Science University became the first Pacific Northwest health system to treat a patient with the SetPoint System, an FDA-approved neuroimmune modulation therapy for rheumatoid arthritis. The device targets the vagus nerve to reduce inflammation, and SetPoint Medical plans to evaluate its platform for multiple sclerosis and Crohn's disease.BioSpaceSetPoint® System Used for First Time in Pacific Northwest to Treat Patients with Rheumatoid Arthritis in Clinical PracticeOregon Health & Science University became the first Pacific Northwest health system to treat a patient with the SetPoint System, an FDA-approved neuroimmune modulation therapy for rheumatoid arthritis. The device targets the vagus nerve to reduce inflammation, and SetPoint Medical plans to evaluate its platform for multiple sclerosis and Crohn's disease.